Karyopharm Therapeutics Reports Q2 2026 Financial Results with $33.4M Revenue Decline

Karyopharm Therapeutics Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $33.4 million, a decrease of 12% compared to $37.9 million in the same period last year. The decline was primarily driven by a significant drop in license and other revenue, which fell by 68% to $2.7 million, largely due to the expiration of reimbursement obligations from its partner Menarini. In contrast, product revenue from its lead drug, XPOVIO, increased by 4% to $30.8 million, reflecting consistent demand in a competitive market. For the first half of 2026, total revenue was $68.5 million, slightly up from $67.9 million in the prior year, with product revenue rising 18% to $59.9 million.

Operating expenses for the second quarter decreased by 10% to $56.0 million, driven by reductions in research and development costs, which fell by 12% to $29.0 million, and selling, general, and administrative expenses, which decreased by 9% to $25.9 million. The company reported a loss from operations of $22.5 million, an improvement from a loss of $24.4 million in the same quarter of 2025. However, total other expenses surged to $44.5 million, primarily due to non-cash items related to the fair value remeasurement of embedded derivatives and liability-classified common stock warrants, leading to a net loss of $67.0 million for the quarter, compared to a loss of $37.3 million a year earlier.

Karyopharm's balance sheet as of June 30, 2026, showed total assets of $111.3 million, with cash, cash equivalents, and investments amounting to $65.1 million. The company reported an accumulated deficit of $1.8 billion and a stockholders' deficit of $330.2 million. The increase in liabilities was notable, with current liabilities rising to $134.2 million, up from $92.1 million at the end of 2025, largely due to increased borrowings under its senior secured term loan.

Strategically, Karyopharm is focusing on advancing its clinical programs, particularly for myelofibrosis, and plans to submit a supplemental New Drug Application (sNDA) to the FDA in August 2026 for selinexor in combination with ruxolitinib. The company is also actively exploring financing opportunities to extend its cash runway, as it anticipates needing additional capital to meet upcoming obligations, including a $15.8 million principal payment due on September 10, 2026. The company has expressed substantial doubt regarding its ability to continue as a going concern within the next year without securing additional funding.

Looking ahead, Karyopharm aims to leverage its existing liquidity and revenue streams to fund operations into September 2026 while navigating the challenges posed by its financial obligations. The company is evaluating various strategic alternatives to maximize shareholder value and ensure the continuation of its operations amid ongoing losses and market pressures.